Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...

For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...

If your doctor thinks you have non-small-cell lung cancer (NSCLC), they will usually look for a change (they may call it a mutation) in a gene called the EGFR gene. Normally, EGFR helps healthy cells ...

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options. Dr. Girindra Raval sat down for an interview ...

New EGFR-targeting combos may improve response rates and durability for patients with head and neck cancer.

CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...

Glioma remains one of the deadliest brain cancers, characterized by aggressive growth and limited treatment options. In a new study, researchers from Ningxia Medical University uncovered that choline ...

As eGFR decreased, risks for 30-day hospital readmission or death increased for patients with chronic kidney disease, according to study data published in Clinical Journal of the American Society of ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.